Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Exp Neurol. 2015 Jul 26;273:1–10. doi: 10.1016/j.expneurol.2015.07.021

Table 1.

Canine subjects used in the study. The “X” marks studies in which a particular dog was included.

Subject Group DTI RT-PCR Myelin
composition
Age at
Necropsy
I-319 CTL X X X 19 m
I-318 CTL X X X 19 m
B-301 CTL X X X 30 m
I-262 CTL X X X 29 m
I-371* MPS X X 20 m
I-388* MPS X X 17 m
I-392* MPS X X 17 m
I-393* MPS X X 17 m
I-399 MPS X 21 m
I-272 MPS X X X 25 m
I-266 MPS X X X 25 m
I-267 MPS X X X 26 m
I-265 MPS X X X 26 m
I-394 MTr X X X 21 m
I-400 MTr X X X 21 m
I-402 MTr X X X 21 m
I-413 MTr X X X 21 m

MPS: mucopolysaccharidosis; MTr: MPS I dogs treated with intrathecal recombinant human alpha-l-iduronidase; DTI: diffusion tensor imaging; RT-PCR: reverse transcriptase-polymerase chain reaction.

Dogs that received intra-articular alpha-l-iduronidase are marked with an *.